Clinical efficacy of chemoembolization with drug-infused gelatin sponge microparticles for arterioportal shunts in patients with hepatocellular carcinoma
10.3760/cma.j.cn112149-20231108-00363
- VernacularTitle:载药明胶海绵颗粒栓塞治疗肝细胞癌合并肝动脉-门静脉分流的临床疗效
- Author:
Yiyuan XIE
1
;
Tong WANG
;
Yanchao ZHANG
;
Lequn WEI
;
Quanping XIAO
;
Tingwei DU
;
Lili SHI
;
Huanzhang NIU
Author Information
1. 河南科技大学临床医学院 河南科技大学第一附属医院介入科，洛阳 471003
- Keywords:
Carcinoma, hepatocellular;
Transcatheter intraarterial chemoembolization;
Gelatin sponge, absorbable;
Microparticle embolic agent
- From:
Chinese Journal of Radiology
2024;58(5):517-522
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the clinical efficacy of chemoembolization with doxorubicin-infused gelatin sponge microparticles in the amelioration of arterioportal shunting (APS) in patients afflicted with hepatocellular carcinoma (HCC).Methods:A retrospective investigation was conducted on 9 HCC patients admitted between January 2020 and December 2022 with concomitant moderate-to-severe APS who underwent GSM-transarterial chemoembolization (TACE). Hepatic artery digital subtraction angiography (DSA) was employed to ascertain the magnitude of improvement in arteriovenous shunts, utilization of modified response evaluation criteria in solid tumors facilitated the appraisal of short-term clinical outcomes. Follow-up records documented survival duration, along with quantitative parameters such as the longest diameter of tumor lesions and serum alpha-fetoprotein (AFP) levels before and after treatment. The Wilcoxon rank-sum test was utilized to compare the differences of these quantitative parameters before and after treatment.Results:The APS amelioration rates were 100% and 88.9% at immediate and recent postoperatively, respectively. The oncological response rate was 77.8% (7/9), and the complete necrosis rate was 22.2% (2/9) at three months postoperatively, the 1-year survival rate was 100%. Following treatment, a significant reduction was observed in the tumor′s longitudinal diameter [4.32(3.88,6.63)cm] and serum AFP levels [13.50 (7.55, 29.60) μg/L], compared to the pre-treatment values of the tumor′s longitudinal diameter [5.20(4.58,8.57)cm] and serum AFP levels [524.30 (320.65, 1 046.15) μg/L] ( P<0.05 for all). Conclusion:Doxorubicin-infused GSM-TACE is both feasible and efficacious in the first treatment of HCC concomitant with APS and represents a better clinical alternative.
